Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway

21 Apr 2015

Abstract excerpt

BACKGROUND: Novel-targeted therapies are in rapid development for the treatment of acute lymphoblastic leukemia (ALL) to overcome resistance and decrease toxicity. Survivin, a member of the inhibitor of apoptosis gene family and chromosome passenger complex, is critical in a variety of human cancers, including ALL. A well-established suppressor of survivin has been the small molecule, YM155. Reports are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Cell death mechanisms and regulation
Share to Chronic Myeloid Leukemia Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25895498
DOI: 10.1186/s13045-015-0132-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathwayPMID 25895498Read ↗

AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemiaSemantic proximity Read ↗

Emerging Targeted Therapy for Specific Genomic Abnormalities in Acute Myeloid Leukemia.Semantic proximity Read ↗

The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph− acute lymphoblastic leukemia cellsSemantic proximity Read ↗

Proteomic profiling reveals pleiotropic antimetabolite activity of triciribine in acute lymphoblastic leukemiaSemantic proximity Read ↗

Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia.Semantic proximity Read ↗

The FLT3 Internal Tandem Duplication Mutation Is a Secondary Target of the Aurora B Kinase Inhibitor AZD1152-HQPA in Acute Myelogenous Leukemia CellsSemantic proximity Read ↗

WEE1 inhibition induces glutamine addiction in T-cell acute lymphoblastic leukemiaSemantic proximity Read ↗

DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemiaSemantic proximity Read ↗

Distinct Responses to Menin Inhibition and Synergy with DOT1L Inhibition in KMT2A-Rearranged Acute Lymphoblastic and Myeloid Leukemia.Semantic proximity Read ↗

AZD1152 Rapidly and Negatively Affects the Growth and Survival of Human Acute Myeloid Leukemia Cells <i>In vitro</i> and <i>In vivo</i>Semantic proximity Read ↗

Novel RNA Polymerase I and Cyclin Dependent Kinase combination therapy for the treatment of aggressive Acute Myeloid LeukemiaSemantic proximity Read ↗

ATM inhibition enhances the efficacy of radiation across distinct molecular subgroups of pediatric high-grade gliomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.